BWI: Indian Medical Innovation Comes to the Forefront with Nutech Mediworld’s Groundbreaking Clinical Treatment Findings on Human Embryonic Stem Cell Therapy

Press release from Business Wire India
Source: Nutech Mediworld
Friday, June 08, 2012 10:00 AM IST (04:30 AM GMT)
Editors: General: Consumer interest, People; Business: Advertising, PR & marketing, Business services, Healthcare, biotechnology & pharmaceutical, Major diversified industrial groups; Technology; Healthcare
--------------------------------------------------
Indian Medical Innovation Comes to the Forefront with Nutech Mediworld's Groundbreaking Clinical Treatment Findings on Human Embryonic Stem Cell Therapy
Dr. C. Rangarajan, Chairman of the Economic Advisory Council to the Prime Minister, Dr. Amiram Katz, Yale University School of Medicine and other dignitaries present on the occasion

New Delhi, Delhi, India, Friday, June 08, 2012 -- (Business Wire India) -- Indian medical innovation once again came to the forefront with Dr. Geeta Shroff, founder and medical director of Nutech Mediworld, announcing groundbreaking clinical findings on the safety and efficacy of Human Embryonic Stem Cell (hESC) therapy in the treatment of various medical conditions. The clinical study reports were released by the Chief Guest Dr. C. Rangarajan, Chairman of the Economic Advisory Council to the Prime Minister, in the presence of eminent personalities and doctors.

This was followed by a symposium entitled 'Human Embryonic Stem Cell Therapy: Life-changing innovation from India' with the keynote address by Dr. Amiram Katz from the Yale University School of Medicine. Several leading medical experts and more than 50 eminent doctors were present on the occasion. The Clinical Study Reports released provide in-depth safety and efficacy data of hESC Therapy in (1) Multiple Sclerosis, (2) Cerebral Palsy, (3) Stroke, (4) Chronic Spinal Cord Injury, (5) Lyme disease, and (6) ALS.

Commending Nutech Mediworld's efforts, Dr. Rangarajan said, "I congratulate Nutech Mediworld and Dr. Geeta Shroff for their pioneering work in demonstrating the safety and efficacy of Human Embryonic Stem Cell therapy. We must support and encourage medical practitioners like her who have the vision and tenacity to focus on research aimed at bringing innovative healthcare technologies to the world. Medical research and innovation in India should aim to alleviate the suffering of millions, and Dr. Shroff's efforts are a major step forward in this direction."

According to Dr. Geeta Shroff, "We at Nutech Mediworld are pleased to release the findings of our clinical work over the last 10 years across 1000 patients in the field of Human Embryonic Stem Cell therapy. We have developed a ready-to-use product with a shelf life of six months. It is our vision to make this available globally, as a first line of treatment, to safely and effectively improve the quality of life of patients suffering from conditions presently labeled incurable or terminal."

Till date, Nutech Mediworld has treated over 1000 patients from 43 countries, with nearly 100 patients from the USA. Conditions treated include spinal injuries, multiple sclerosis, Parkinson's disease, diabetes, Lyme disease, cerebral palsy and autism. Remarkably, 33% of patients undertaking this therapy are doctors and their immediate relatives, demonstrating their belief in the therapy. As part of its social responsibility initiative, 15% of the patients are treated free of cost at Nutech Mediworld.

About:

Nutech Mediworld is the first facility in the world to provide Human Embryonic Stem Cell therapy. Over the last 10 years, the technology has been used clinically to treat more than 1000 patients suffering from conditions all presently labeled incurable or terminal. Nutech Mediworld has developed disease-wise efficacy assessment parameters, and also established the quality and safety protocol to treat patients with hESC transplantation - including cell type, route, dosage, frequency, period and schedule. The technology has evolved in the form of a ready-to-use product with a shelf-life of 6 months, so that it can be made available to patients globally at their convenience. The technology has patents applied for worldwide.

Dr. Geeta Shroff, the founder and medical director of Nutech Mediworld, has done pioneering work in developing a commercially viable technology to isolate stem cells, culture them, prepare them for clinical application, and store them in a ready-to-use form. She was the first to develop purely human embryonic stem cell lines using just a single, spare, pre-implantation stage embryo from a regular IVF cycle. This was done in 2000 with the patient's consent, in full compliance with the regulatory guidelines. The same original embryonic stem cell line is still being used, without repeated need for embryos.



CONTACT DETAILS
Sanjiv Singh, +91 9818430943
Ruby Sinha, +91 981163965

KEYWORDS
CONSUMER, PEOPLE, MARKETING, BUSINESS SERVICES, HEALTHCARE, GROUPS, TECHNOLOGY, HEALTHCARE

If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com